M. Kann, A. Schmitz, B. Rabe (2007)
Intracellular transport of hepatitis B virus.World journal of gastroenterology, 13 1
A. Gehring, U. Protzer (2019)
Targeting Innate and Adaptive Immune Responses to Cure Chronic HBV Infection.Gastroenterology, 156 2
E. Gane, M. Yuen, Q. Bo, C. Schwabe, T. Tanwandee, Sudip Das, Yuyan Jin, Lu Gao, Xue Zhou, Yifan Wang, Sheng Feng, D. Meinel, Mingfen Zhu (2019)
FRI-219-RO7049389, a core protein allosteric modulator, demonstrates robust decline in HBV DNA and HBV RNA in chronic HBV infected patientsJournal of Hepatology
T. Liang, Tim Block, B. McMahon, M. Ghany, S. Urban, Ju-Tao Guo, S. Locarnini, F. Zoulim, Kyong‐Mi Chang, A. Lok (2015)
Present and future therapies of hepatitis B: From discovery to cureHepatology, 62
H. Wedemeyer, K. Schöneweis, P. Bogomolov, Natalia Voronkova, V. Chulanov, T. Stepanova, B. Bremer, L. Allweiss, M. Dandri, J. Burhenne, W. Haefeli, S. Ciesek, U. Dittmer, A. Alexandrov, S. Urban (2019)
GS-13-Final results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of myrcludex B in cwith PEG-interferon Alpha 2a in patients with chronic HBV/HDV co-infectionJournal of Hepatology
P. Fisicaro, C. Valdatta, M. Massari, E. Loggi, E. Biasini, L. Sacchelli, M. Cavallo, E. Silini, P. Andreone, G. Missale, C. Ferrari (2010)
Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B.Gastroenterology, 138 2
C. Real, M. Werner, A. Paul, G. Gerken, J. Schlaak, A. Vaillant, R. Broering (2017)
Nucleic acid-based polymers effective against hepatitis B Virus infection in patients don’t harbor immunostimulatory properties in primary isolated liver cellsScientific Reports, 7
B. Ye, Xianbao Liu, Xuefen Li, Haishen Kong, Li Tian, Yunbo Chen (2015)
T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significanceCell Death & Disease, 6
A. Gehring, S. Xue, Z. Ho, D. Teoh, C. Ruedl, A. Chia, S. Koh, S. Lim, M. Maini, H. Stauss, A. Bertoletti (2011)
Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines.Journal of hepatology, 55 1
C. Franke, U. Matschl, M. Bruns (2007)
Enzymatic treatment of duck hepatitis B virus: topology of the surface proteins for virions and noninfectious subviral particles.Virology, 359 1
Huan Yan, Guocai Zhong, Guangwei Xu, Wenhui He, Zhiyi Jing, Zhenchao Gao, Yi Huang, Yonghe Qi, B. Peng, Haimin Wang, Liran Fu, Mei Song, Pan Chen, Wenqing Gao, Bijie Ren, Yinyan Sun, Tao Cai, Xiaofeng Feng, J. Sui, Wenhui Li (2012)
Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D viruseLife, 1
S. Urban, R. Bartenschlager, R. Kubitz, F. Zoulim (2014)
Strategies to inhibit entry of HBV and HDV into hepatocytes.Gastroenterology, 147 1
Kelong Han, J. Cremer, R. Elston, S. Oliver, S. Baptiste-Brown, Shuguang Chen, D. Gardiner, M. Davies, Joanne Saunders, R. Hamatake, Jan Losos, M. Leivers, Steve Hood, Frans Berg, M. Paff, J. Ritter, D. Theodore (2019)
A Randomized, Double‐Blind, Placebo‐Controlled, First‐Time‐in‐Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of GSK3389404 in Healthy SubjectsClinical Pharmacology in Drug Development, 8
Zhiyong Ma, Q. Cao, Y. Xiong, E. Zhang, Mengji Lu (2018)
Interaction between Hepatitis B Virus and Toll-Like Receptors: Current Status and Potential Therapeutic Use for Chronic Hepatitis BVaccines, 6
(2019)
RO7049389, a core protein allosteric modulator, demonstrates robust decline in HBV DNA and HBV RNA in chronic HBV infected patientsSci. HBV Cure
H. Janssen, M. Brunetto, Y. Kim, C. Ferrari, B. Massetto, Anh-Hoa Nguyen, A. Joshi, J. Woo, A. Lau, A. Gaggar, G. Subramanian, E. Yoshida, S. Ahn, N. Tsai, S. Fung, E. Gane (2017)
Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B.Journal of hepatology, 68 3
E. Spyrou, Coleman Smith, M. Ghany (2020)
Hepatitis B: Current Status of Therapy and Future Therapies.Gastroenterology clinics of North America, 49 2
Connie Kang, Yahiya Syed (2020)
Bulevirtide: First ApprovalDrugs, 80
M. Galarreta, A. Lujambio (2017)
Therapeutic editing of hepatocyte genome in vivo.Journal of hepatology, 67 4
P. Bogomolov, A. Alexandrov, Natalia Voronkova, M. Macievich, K. Kokina, M. Petrachenkova, T. Lehr, Florian Lempp, H. Wedemeyer, M. Haag, M. Schwab, W. Haefeli, A. Blank, S. Urban (2016)
Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study.Journal of hepatology, 65 3
M. Yuen, I. Schiefke, Jung‐Hwan Yoon, S. Ahn, J. Heo, Ju Kim, H. Chan, K. Yoon, H. Klinker, M. Manns, J. Petersen, T. Schluep, J. Hamilton, B. Given, C. Ferrari, Ching‐lung Lai, S. Locarnini, R. Gish (2020)
RNA Interference Therapy With ARC‐520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B InfectionHepatology (Baltimore, Md.), 72
A. Bertoletti, N. Bert (2018)
Immunotherapy for Chronic Hepatitis B Virus InfectionGut and Liver, 12
F. Zoulim, O. Lenz, J. Vandenbossche, W. Talloen, T. Verbinnen, I. Moscalu, A. Streinu-Cercel, S. Bourgeois, M. Buti, J. Crespo, Juan Pascasio, C. Sarrazin, T. Vanwolleghem, U. Shukla, J. Fry, J. Yogaratnam (2020)
JNJ-56136379, an HBV Capsid Assembly Modulator, is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients with Chronic Infection.Gastroenterology
Jia Liu, E. Zhang, Zhiyong Ma, Weimin Wu, A. Kosinska, Xiaoyong Zhang, Inga Möller, Pia Seiz, D. Glebe, Baoju Wang, Dongliang Yang, Mengji Lu, M. Roggendorf (2014)
Enhancing Virus-Specific Immunity In Vivo by Combining Therapeutic Vaccination and PD-L1 Blockade in Chronic Hepadnaviral InfectionPLoS Pathogens, 10
J. Nayagam, Z. Cargill, K. Agarwal (2020)
The Role of RNA Interference in Functional Cure Strategies for Chronic Hepatitis BCurrent Hepatology Reports, 19
T. Asselah, D. Loureiro, I. Tout, C. Castelnau, N. Boyer, P. Marcellin, A. Mansouri (2020)
Future treatments for hepatitis delta virus infectionLiver International, 40
E. Gane, Daniel Verdon, A. Brooks, A. Gaggar, Anh-Hoa Nguyen, G. Subramanian, C. Schwabe, P. Dunbar (2019)
Anti-PD-1 Blockade with Nivolumab with and without Therapeutic Vaccination for Virally Suppressed Chronic Hepatitis B: A Pilot Study.Journal of hepatology
M. Pfefferkorn, S. Böhm, T. Schott, D. Deichsel, C. Bremer, K. Schröder, W. Gerlich, D. Glebe, T. Berg, F. Bömmel (2017)
Quantification of large and middle proteins of hepatitis B virus surface antigen (HBsAg) as a novel tool for the identification of inactive HBV carriersGut, 67
Jieliang Chen, Wen Zhang, Junyu Lin, Fan Wang, Min Wu, Cuncun Chen, Ye Zheng, Xiuhua Peng, Jianhua Li, Zhenghong Yuan (2014)
An efficient antiviral strategy for targeting hepatitis B virus genome using transcription activator-like effector nucleases.Molecular therapy : the journal of the American Society of Gene Therapy, 22 2
M. Bazinet, V. Pântea, G. Placinta, I. Moscalu, V. Cebotarescu, Lilia Cojuhari, P. Jimbei, L. Iarovoi, Valentina Smeşnoi, Tatiana Musteață, A. Jucov, U. Dittmer, A. Krawczyk, A. Vaillant (2020)
Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy.Gastroenterology
T. Yip, V. Wong, Y. Tse, L. Liang, Vicki Hui, Xinrong Zhang, Guanlin Li, G. Lui, H. Chan, G. Wong (2020)
Similarly low risk of hepatocellular carcinoma after either spontaneous or nucleos(t)ide analogue‐induced hepatitis B surface antigen lossAlimentary Pharmacology & Therapeutics, 53
M. Yuen, E. Gane, D. Kim, F. Weilert, Henry Chan, J. Lalezari, S. Hwang, Tuan Nguyen, O. Flores, G. Hartman, Sandy Liaw, O. Lenz, T. Kakuda, W. Talloen, C. Schwabe, K. Klumpp, N. Brown (2019)
Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection.Gastroenterology, 156 5
S. Naggie, A. Lok (2020)
New Therapeutics for Hepatitis B: The Road to Cure.Annual review of medicine
N. Chai, H. Chang, E. Nicolas, Ziying Han, M. Jarnik, Johnm Taylor (2008)
Properties of Subviral Particles of Hepatitis B VirusJournal of Virology, 82
I. Tout, D. Loureiro, A. Mansouri, V. Soumelis, N. Boyer, T. Asselah (2020)
Hepatitis B Surface Antigen Seroclearance: Immune Mechanisms, Clinical Impact, Importance for Drug Development.Journal of hepatology
X. Hong, Elena Kim, Haitao Guo (2017)
Epigenetic regulation of hepatitis B virus covalently closed circular DNA: Implications for epigenetic therapy against chronic hepatitis BHepatology, 66
M. Cornberg, A. Lok, N. Terrault, F. Zoulim, T. Berg, M. Brunetto, S. Buchholz, M. Buti, H. Chan, Kyong‐Mi Chang, M. Dandri, G. Dusheiko, J. Feld, C. Ferrari, M. Ghany, H. Janssen, P. Kennedy, P. Lampertico, Jake Liang, S. Locarnini, M. Maini, P. Mishra, G. Papatheodoridis, J. Petersen, S. Schlottmann, Su-Wen Wang, H. Wedemeyer, N. Afdhal, D. Apelian, N. Brown, M. Beumont‐Mauviel, G. Cloherty, M. Cornberg, T. Dickens, Eric Donaldson, A. Gaggar, B. Given, U. Lopatin, A. Lok, V. Miller, G. Picchio, P. Revill, N. Terrault, A. Vaillant, L. Vernoux, C. Wat, J. Young, F. Zoulim (2019)
Guidance for Design and Endpoints of Clinical Trials in Chronic Hepatitis B—Report From the 2019 EASL‐AASLD HBV Treatment Endpoints ConferenceHepatology, 71
T. Asselah, D. Loureiro, N. Boyer, A. Mansouri (2019)
Targets and future direct-acting antiviral approaches to achieve hepatitis B virus cure.The lancet. Gastroenterology & hepatology, 4 11
M. Bazinet, V. Pântea, V. Cebotarescu, Lilia Cojuhari, P. Jimbei, J. Albrecht, P. Schmid, F. Gal, E. Gordien, A. Krawczyk, H. Mijočević, H. Karimzadeh, M. Roggendorf, A. Vaillant (2017)
Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.The lancet. Gastroenterology & hepatology, 2 12
J. Summers, A. O'Connell, I. Millman (1975)
Genome of hepatitis B virus: restriction enzyme cleavage and structure of DNA extracted from Dane particles.Proceedings of the National Academy of Sciences of the United States of America, 72 11
M. Blanchet, C. Sureau (2007)
Infectivity Determinants of the Hepatitis B Virus Pre-S Domain Are Confined to the N-Terminal 75 Amino Acid ResiduesJournal of Virology, 81
Xing Liu, Ruidong Hao, Shuliang Chen, D. Guo, Yu Chen (2015)
Inhibition of hepatitis B virus by the CRISPR/Cas9 system via targeting the conserved regions of the viral genome.The Journal of general virology, 96 8
K. Krebs, N. Böttinger, Li-Rung Huang, M. Chmielewski, S. Arzberger, G. Gasteiger, C. Jäger, E. Schmitt, F. Bohne, M. Aichler, W. Uckert, H. Abken, M. Heikenwalder, P. Knolle, U. Protzer (2013)
T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice.Gastroenterology, 145 2
Ci Song, Jian Zhu, Zijun Ge, Chengxiao Yu, Ting Tian, Hui Wang, Jing Han, Hongbing Shen, J. Dai, Jianquan Lu, Zhibin Hu (2019)
Spontaneous Seroclearance of Hepatitis B Surface Antigen and Risk of Hepatocellular CarcinomaClinical Gastroenterology & Hepatology, 17
(2018)
First results with rna interference (rnai) in chronic hepatitis b (chb) using ARO-HBV
B. Jiang, E. Hildt (2020)
Intracellular Trafficking of HBV ParticlesCells, 9
Xiaoli Ma, J. Lalezari, T. Nguyen, H. Bae, E. Schiff, S. Fung, M. Yuen, T. Hassanein, H. Hann, M. Elkhashab, D. Dieterich, M. Sulkowski, P. Kwo, R. Nahass, K. Agarwal, A. Ramji, J. Park, N. Ravendhran, S. Chan, F. Weilert, Steven‐Huy Han, W. Ayoub, E. Gane, I. Jacobson, Michael Bennett, Qi Huang, R. Yan, V. Huey, Eric Ruby, Sandy Liaw, R. Colonno, U. Lopatin (2019)
LBO-06-Interim safety and efficacy results of the ABI-H0731 phase 2a program exploring the combination of ABI-H0731 with Nuc therapy in treatment-naive and treatment-suppressed chronic hepatitis B patientsJournal of Hepatology
S. Lim, Jennielyn Agcaoili, N. Souza, E. Chan (2019)
Therapeutic vaccination for chronic hepatitis B: A systematic review and meta‐analysisJournal of Viral Hepatitis, 26
Jianming Hu, Kuancheng Liu (2017)
Complete and Incomplete Hepatitis B Virus Particles: Formation, Function, and ApplicationViruses, 9
M. Nassal (2015)
HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis BGut, 64
(2019)
First clinical experience with RNA interference-based triple combination therapy in chronic hepatitis B: JNJ-3989, JNJ-6379 and a Nucleos (t) ide analogue
C. Seeger, W. Mason (2015)
Molecular biology of hepatitis B virus infection.Virology, 479-480
(2020)
Efficacy of Lenvervimab , a Recombinant Human Immunoglobulin , in Treatment of Chronic Hepatitis B Virus Infection
International Journal of Molecular Sciences – Unpaywall
Published: Dec 28, 2020
Access the full text.
Sign up today, get DeepDyve free for 14 days.